newsfilter
← Latest News
GlobeNewswire·

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025

Presented positive new clinical data demonstrating high rates of durable complete responses from the Phase 1/2 trial of LYL314 for the treatment of aggressive large B-cell lymphomaInitiated the PiNACLE pivotal trial of